Duloxetine FDA Recall Overview
Duloxetine, sold under brand names including Cymbalta and generic formulations, has faced periodic FDA recalls tied to quality defects, contamination risks, and labeling discrepancies. The FDA maintains an active enforcement report listing duloxetine-related recalls, with recent actions focused on specific manufacturers, dosage strengths, and lot numbers. Investors and patients track these updates through the FDA database and company press releases. For current enforcement details, see the FDA recall database.
Recall classifications under the FDA system range from Class I, indicating a reasonable probability of serious adverse health consequences or death, to Class III, where the product is not likely to cause adverse health consequences. Duloxetine recalls have most often fallen into Class II, where use of the product may cause temporary or medically reversible adverse health consequences. The frequency of these actions reflects the FDA's ongoing oversight of generic drug manufacturing and the complexity of global supply chains.
Companies, Lots, and Reasons for Duloxetine Recalls
Multiple pharmaceutical companies have issued duloxetine recalls in recent years, including Teva, Aurobindo, Dr. Reddy's Laboratories, and other generic manufacturers. Specific recall notices identify affected NDC codes, dosage strengths such as 30 mg and 60 mg capsules, and individual lot numbers printed on the packaging. Common reasons cited include failure of dissolution testing, presence of foreign particles, and deviations from approved manufacturing processes that could affect product quality.
The FDA's recall database allows users to search by drug name, NDC number, or company to find the exact scope of each action. Companies typically initiate voluntary recalls after internal quality assurance reviews or in response to FDA warning letters and inspection findings. Detailed lot-specific information is published in weekly FDA enforcement reports and company press releases, enabling pharmacies and patients to verify whether their stock is affected.
Market Impact and Investor Considerations
Duloxetine is a widely prescribed serotonin-norepinephrine reuptake inhibitor (SNRI) used for major depressive disorder, generalized anxiety disorder, and chronic pain conditions. Recalls can temporarily disrupt supply chains for specific dosage forms and manufacturers, shifting market share toward unaffected producers and authorized generic competitors. The FDA's approval of new generic entrants and the resolution of manufacturing deficiencies typically restore full market availability over time.
For investors, duloxetine recall activity is monitored through SEC filings, company earnings calls, and FDA enforcement reports that signal potential revenue impacts and regulatory risk. Pharmaceutical companies with active duloxetine products must disclose material recall events in their periodic reports under SEC regulations. Market analysts assess the duration and scope of each recall to adjust revenue forecasts and risk ratings for the affected manufacturers and their parent conglomerates.